Clin Oral Investig:全身使用阿奇霉素作为III/IV期牙周炎患者洗牙和根管治疗的辅助治疗手段

2021-10-17 MedSci原创 MedSci原创

长期以来,抗生素一直作为洗牙和根管治疗(SRP)标准治疗方案的辅助疗法。近日,发表于Clin Oral Investig的一项双盲随机平行臂安慰剂对照试验旨在确定阿奇霉素(AZI)作为洗牙和根管治疗(

长期以来,抗生素一直作为洗牙和根管治疗(SRP)标准治疗方案的辅助疗法。近日,发表于Clin Oral Investig的一项双盲随机平行臂安慰剂对照试验旨在确定阿奇霉素(AZI)作为洗牙和根管治疗(SRP)的辅助药物,与安慰剂相比,是否能减少III/IV期牙周炎患者治疗后12个月出现探诊深度(PD)≥5mm和探针出血(BOP)部位的数量。

研究共纳入40名III/IV期牙周炎患者在7天内分两次接受了牙周治疗,然后接受全身抗生素治疗(n = 20;AZI 500毫克/天,3天)或安慰剂(n = 20)。在3个月、6个月和9个月的随访中,对残留的病变部位(DS)--PD≥5毫米和BOP的部位--进行了额外的机械治疗。主要结果变量是12个月复查时DS的数量。使用多变量多层次逻辑回归模型,评估了性别、年龄、抗生素治疗、牙龈卟啉菌或放线菌的存在、吸烟、牙齿是磨牙和齿间位置的影响。

 

结果显示,12个月后,试验组(中位数(Me)=4,四分位数范围(IQR)=0-6)和对照组(Me=3,IQR=1-6.5)的DS数量相似。两组在牙周参数方面都有实质性但相当的改善,在最初的浅层或深层部位没有组间差异。逻辑回归显示,磨牙(OR = 0.29; p < 0.001)和吸烟者(OR = 0.36; p = 0.048)的DS愈合的OR较低。

综上所述,该研究结果表明,III/IV期牙周炎患者在12个月的重新评估中,无论治疗类型如何,牙周参数和残余DS的数量都有明显的改善。但是,与SRP加安慰剂相比,AZI+SRP治疗12个月后在牙周参数或PD≥5mm+BOP的持续部位数量方面没有提供额外的益处。

 

原始出处:

 

Katja Povšič, et al., Systemic azithromycin as an adjunct to scaling and root planing in patients with stage III/IV periodontitis: 12-month results of a randomized controlled clinical trial. Clin Oral Investig. 2021 Oct;25(10):5997-6006. doi: 10.1007/s00784-021-03906-8.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051711, encodeId=c33f2051e11f9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 14:08:27 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020683, encodeId=fb082020683a1, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Fri Jul 08 09:08:27 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916488, encodeId=45af191648873, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Sep 11 18:08:27 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068238, encodeId=e0df1068238cf, content=AZI+SRP治疗乏证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201024/67558ad1510145499d4ffbb4720a49f0/db11b160e7384fb99f31c2853d79dc4c.jpg, createdBy=74815279084, createdName=薛鹏, createdTime=Mon Nov 08 20:22:28 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1451369, encodeId=d7bc145136960, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 19 10:08:27 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523049, encodeId=6b611523049ce, content=<a href='/topic/show?id=c72462241ff' target=_blank style='color:#2F92EE;'>#根管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62241, encryptionId=c72462241ff, topicName=根管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5e11492705, createdName=zhaozhouchifen, createdTime=Tue Oct 19 10:08:27 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051711, encodeId=c33f2051e11f9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 14:08:27 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020683, encodeId=fb082020683a1, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Fri Jul 08 09:08:27 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916488, encodeId=45af191648873, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Sep 11 18:08:27 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068238, encodeId=e0df1068238cf, content=AZI+SRP治疗乏证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201024/67558ad1510145499d4ffbb4720a49f0/db11b160e7384fb99f31c2853d79dc4c.jpg, createdBy=74815279084, createdName=薛鹏, createdTime=Mon Nov 08 20:22:28 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1451369, encodeId=d7bc145136960, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 19 10:08:27 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523049, encodeId=6b611523049ce, content=<a href='/topic/show?id=c72462241ff' target=_blank style='color:#2F92EE;'>#根管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62241, encryptionId=c72462241ff, topicName=根管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5e11492705, createdName=zhaozhouchifen, createdTime=Tue Oct 19 10:08:27 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2022-07-08 小几洁
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051711, encodeId=c33f2051e11f9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 14:08:27 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020683, encodeId=fb082020683a1, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Fri Jul 08 09:08:27 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916488, encodeId=45af191648873, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Sep 11 18:08:27 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068238, encodeId=e0df1068238cf, content=AZI+SRP治疗乏证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201024/67558ad1510145499d4ffbb4720a49f0/db11b160e7384fb99f31c2853d79dc4c.jpg, createdBy=74815279084, createdName=薛鹏, createdTime=Mon Nov 08 20:22:28 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1451369, encodeId=d7bc145136960, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 19 10:08:27 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523049, encodeId=6b611523049ce, content=<a href='/topic/show?id=c72462241ff' target=_blank style='color:#2F92EE;'>#根管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62241, encryptionId=c72462241ff, topicName=根管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5e11492705, createdName=zhaozhouchifen, createdTime=Tue Oct 19 10:08:27 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2022-09-11 juliusluan78
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051711, encodeId=c33f2051e11f9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 14:08:27 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020683, encodeId=fb082020683a1, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Fri Jul 08 09:08:27 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916488, encodeId=45af191648873, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Sep 11 18:08:27 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068238, encodeId=e0df1068238cf, content=AZI+SRP治疗乏证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201024/67558ad1510145499d4ffbb4720a49f0/db11b160e7384fb99f31c2853d79dc4c.jpg, createdBy=74815279084, createdName=薛鹏, createdTime=Mon Nov 08 20:22:28 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1451369, encodeId=d7bc145136960, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 19 10:08:27 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523049, encodeId=6b611523049ce, content=<a href='/topic/show?id=c72462241ff' target=_blank style='color:#2F92EE;'>#根管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62241, encryptionId=c72462241ff, topicName=根管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5e11492705, createdName=zhaozhouchifen, createdTime=Tue Oct 19 10:08:27 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2021-11-08 薛鹏

    AZI+SRP治疗乏证据支持

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2051711, encodeId=c33f2051e11f9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 14:08:27 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020683, encodeId=fb082020683a1, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Fri Jul 08 09:08:27 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916488, encodeId=45af191648873, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Sep 11 18:08:27 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068238, encodeId=e0df1068238cf, content=AZI+SRP治疗乏证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201024/67558ad1510145499d4ffbb4720a49f0/db11b160e7384fb99f31c2853d79dc4c.jpg, createdBy=74815279084, createdName=薛鹏, createdTime=Mon Nov 08 20:22:28 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1451369, encodeId=d7bc145136960, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 19 10:08:27 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523049, encodeId=6b611523049ce, content=<a href='/topic/show?id=c72462241ff' target=_blank style='color:#2F92EE;'>#根管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62241, encryptionId=c72462241ff, topicName=根管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5e11492705, createdName=zhaozhouchifen, createdTime=Tue Oct 19 10:08:27 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2051711, encodeId=c33f2051e11f9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 14:08:27 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020683, encodeId=fb082020683a1, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Fri Jul 08 09:08:27 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916488, encodeId=45af191648873, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Sep 11 18:08:27 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068238, encodeId=e0df1068238cf, content=AZI+SRP治疗乏证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201024/67558ad1510145499d4ffbb4720a49f0/db11b160e7384fb99f31c2853d79dc4c.jpg, createdBy=74815279084, createdName=薛鹏, createdTime=Mon Nov 08 20:22:28 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1451369, encodeId=d7bc145136960, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 19 10:08:27 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523049, encodeId=6b611523049ce, content=<a href='/topic/show?id=c72462241ff' target=_blank style='color:#2F92EE;'>#根管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62241, encryptionId=c72462241ff, topicName=根管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5e11492705, createdName=zhaozhouchifen, createdTime=Tue Oct 19 10:08:27 CST 2021, time=2021-10-19, status=1, ipAttribution=)]

相关资讯

Cell Rep:早年接触抗生素影响晚年健康和寿命

最近,研究人员研究了生命早期抗生素暴露对健康的、正常饲料喂养的野生型小鼠的影响。

Liver Cancer:免疫治疗期间使用抗生素会增加晚期肝癌患者的死亡率

免疫治疗期间同时使用抗生素与晚期 HCC 患者的更高死亡率相关

Liver Cancer:肝细胞癌患者早期抗生素暴露反而更有可能从免疫治疗中获益

研究表明, 肝细胞癌患者中早期抗生素(ATB)使用(ICI治疗前30天或治疗后30天内)反而有可能从免疫治疗中获益,这值得进一步研究。

JGH: 术后连续三天使用抗生素可以降低乙型肝炎病毒相关肝细胞癌肝切除术后的感染率

肝细胞癌目前仍然是威胁人类生命健康的重大疾病,手术仍然是肝细胞癌 (HCC) 患者最常用的治愈性治疗方法。

J Infection:接受门诊胃肠外抗生素治疗 (OPAT) 的感染性心内膜炎患者预后的临床预测因素

感染性心内膜炎 (IE) 是一种严重且可能致命的感染,通常需要长时间的口服胃肠外抗菌治疗。

Infection:抗生素治疗并不能改善新冠病毒感染患者的全因死亡率和疾病进展

由于在流感等呼吸道病毒感染中,细菌重叠感染可导致更高的发病率和死亡率,需要及时诊断并开始抗生素治疗 (ABT)。